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Abstract
 
Among cells of the immune system, CD11c
 
1
 
 and DEC-205
 
1
 
 splenic dendritic cells primarily
express the cellular receptor (
 
a
 
-dystroglycan [
 
a
 
-DG]) for lymphocytic choriomeningitis virus
(LCMV). By selection, strains and variants of LCMV that bind 
 
a
 
-DG with high affinity are as-
sociated with virus replication in the white pulp, show preferential replication in a majority of
CD11c
 
1
 
 and DEC-205
 
1
 
 cells, cause immunosuppression, and establish a persistent infection.
In contrast, viral strains and variants that bind with low affinity to 
 
a
 
-DG are associated with vi-
ral replication in the red pulp, display minimal replication in CD11c
 
1
 
 and DEC-205
 
1
 
 cells,
and generate a robust anti-LCMV cytotoxic T lymphocyte response that clears the virus infec-
tion. Differences in binding affinities can be mapped to a single amino acid change in the viral
glycoprotein 1 ligand that binds to 
 
a
 
-DG. These findings indicate that receptor–virus interac-
tion on dendritic cells in vivo can be an essential step in the initiation of virus-induced immu-
nosuppression and viral persistence.
Key words: lymphocytic choriomeningitis virus • CD11c
 
1
 
/DEC-205
 
1
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Introduction
 
Understanding the mechanism by which viruses persist and
escape immune surveillance is a key for defining measures
to control and eliminate the infections and diseases they
cause. Viruses that persist often interfere with the differen-
tiated function of infected cells. This, in turn, could per-
turb the normal host homeostasis and lead to disease affect-
ing the nervous, endocrine, immune, and other systems (1,
2). Some viruses that cause persistent infection associated
with significant disease in humans are HIV, the agent of
AIDS, EBV, hepatitis B virus, and hepatitis C virus (for a
review, see reference 3).
Viruses that cause a persistent infection prevent the host’s
immune system from clearing the infectious agent. In many
persisting infections of humans and animals, the infectious
agent has been found in cells of the immune system (4).
Dysfunction or destruction of such cells either directly by
the virus or indirectly through immunopathologic mecha-
nisms leads to immunosuppression. Therefore, it is impor-
tant to determine the nature and expression pattern of the
virus receptor on immune cells, as well as the contribution
of the virus–receptor interaction to the resultant immuno-
suppression.
Lymphocytic choriomeningitis virus (LCMV)
 
1
 
 can infect
cells of the immune system, establish suppression of cellular
and humoral immunoresponses, and cause persistent infec-
tion in its natural host, the mouse (5–8). Other studies
identified the emergence and selection of a viral variant
during the course of LCMV persistence that exhibited an
immunosuppressive phenotype (7, 9–12). In vivo, this im-
munosuppressive variant becomes dominant over the non-
immunosuppressive parental virus in several tissues and
cells, including those of the immune system (11–14). The
parental virus, Armstrong (ARM) 53b, and the vast major-
ity of viruses and variants isolated from the central nervous
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Abbreviations used in this paper:
 
 aa, amino acid(s); APC, allophycocyanin;
ARM, Armstrong; BHK, baby hamster kidney; CNS, central nervous sys-
tem; Cl, clone; DC, dendritic cell; 
 
a
 
-DG, 
 
a
 
-dystroglycan; ECM, extracel-
lular matrix; GP, glycoprotein; IDC, interdigitating dendritic cell; IS,
immunosuppression phenotype; ko, knockout; LCMV, lymphocytic
choriomeningitis virus; NP, nucleoprotein; P, persistence phenotype; RT,
reverse transcriptase; S, small; VOPBA, virus overlay protein binding assay. 
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system (CNS) after intravenous inoculation of adult mice
caused acute infections that were efficiently terminated
within 7–10 d by the host anti-LCMV CD8
 
1
 
 CTLs. In
contrast, viral variants (
 
.
 
95%) isolated from lymphocytes
and macrophages similarly injected into adult mice caused a
generalized immunosuppression as judged by the absence
of a primary CTL response to LCMV and other RNA and
DNA viruses, and an inability to generate antibodies when
immunized with soluble and particulate foreign antigens
(8). It is the inability to generate a sufficient anti-LCMV
CTL response, which is required to clear the virus, that
leads to the development of a persistent infection.
LCMV is a negative-stranded RNA virus whose genome
has two segments, a small (S) RNA and a large (L) RNA.
The S RNA segment encodes the viral glycoprotein (GP)
and nucleoprotein (NP), whereas the L RNA encodes the
L and Z proteins. The GP is synthesized as a precursor pro-
tein (GPc) that is posttranslationally cleaved into GP1
(amino acids [aa] 1–264) and GP2 (aa 265–486). Sequence
comparison between the prototypic immunosuppressive
variant clone 13 (Cl 13) and the nonimmunosuppressive
parental ARM 53b from which Cl 13 was derived showed
five nucleotide changes. Only two of the changes caused aa
substitutions (13, 15–17). One of these aa substitutions is in
position 260 of GP1, with ARM 53b having F and Cl 13 L
(F260L); the other aa change was in position 1079 of the L
protein from K (ARM) to Q (Cl 13).
Recently, 
 
a
 
-dystroglycan (
 
a
 
-DG) was identified as the
receptor for LCMV (18). DG is a highly versatile cellular
receptor for proteins of the extracellular matrix (ECM
[19]). Key findings in the past few years demonstrated that
DG plays a fundamental role in cell assembly and organiza-
tion of basement membranes (for reviews, see references 20
and 21). Cl 13 was found to bind 
 
a
 
-DG with higher affin-
ity than ARM 53b (18). Competitive binding studies using
soluble 
 
a
 
-DG to block virus binding to cells expressing
 
a
 
-DG showed that viral reassortants made between Cl 13
and ARM 53b mapped attachment and infection of the vir-
ion to the S RNA segment (Tishon, A., and M.B.A. Old-
stone, unpublished observations). As ARM 53b and Cl 13
have the same NP aa sequence, but differ at one single aa
position in their GP, F260L in GP1 (16), these results im-
plicated the GP1 mutation in binding of the virus to its cel-
lular receptor. Consistent with this observation is the fact
that only antibodies directed against GP1 exhibited neutral-
izing activity (22, 23).
Previous studies indicated that Cl 13 replicated in
antigen-presenting interdigitating dendritic cells (IDCs),
whereas ARM 53b showed limited replication in these
cells (7). These findings raised four basic questions. First, is
the phenomena observed between Cl 13 and ARM 53b
generalizable to other LCMV isolates; second, do dendritic
cells (DCs) preferentially express 
 
a
 
-DG; third, do quantita-
tive differences between viruses that bind at either high or
low affinity to this receptor determine whether suppression
of the immune response and resultant viral persistence oc-
curs; and fourth, can specific molecular determinants in the
virus GP1 account for differences in binding affinity to
 
a
 
-DG? Here we record three novel observations by char-
acterizing the genome and determining the biology of 36
viral variants isolated from adult immunocompromised and
persistently infected mice. First, viral variants causing im-
munosuppression (IS) and persistent (P) infection (IS
 
1
 
P
 
1
 
)
routinely have a small aliphatic aa primarily in GP1 aa 260,
L (20 out of 23 isolates) or I (3 out of 23 isolates), whereas
in contrast, isolates that have a bulky aromatic aa (F) in
GP1 aa 260 fail to cause both immunosuppression and viral
persistence (IS
 
2
 
P
 
2
 
). Second, all IS
 
1
 
P
 
1
 
 virus variants bound
to 
 
a
 
-DG with at least 1 and most often 2–3 log higher af-
finity than did IS
 
2
 
P
 
2
 
 viruses. Third, in vivo 
 
a
 
-DG was
preferentially expressed on DCs and not T, B, or CD11b
 
1
 
cells. The IS
 
1
 
P
 
1
 
 variants preferentially replicated in cells of
the marginal zone and white pulp area in the spleen,
whereas IS
 
2
 
P
 
2
 
 viruses replicated in cells of the red pulp.
Analysis of spleen cells infected by IS
 
1
 
P
 
1
 
 variants showed
that they were IDCs (CD11c
 
1
 
 and DEC-205
 
1
 
 cells). Over
the course of a 7-d in vivo infection there was a remarkable
enhancement of infection of CD11c
 
1
 
 and DEC-205
 
1
 
 cells
by IS
 
1
 
P
 
1
 
 viruses, with 
 
.
 
50% of CD11c
 
1
 
 cells and 17% of
DEC-205
 
1
 
 cells being infected. By 15 d, 
 
.
 
80% of DEC-
205
 
1
 
 cells were also infected. In contrast, 
 
,
 
1% of T and B
lymphocytes and CD11b
 
1
 
 cells were infected at similar
time points. Taken in total, these findings implicate recep-
tor–virus interaction on DCs in vivo as an essential step in
the initiation of virus-induced immunosuppression and
persistence.
 
Materials and Methods
 
Viruses and Mice Used.
 
LCMV ARM 53b strain is a triple
plaque-purified isolate of ARM CA 1371 (24) and was passaged
in baby hamster kidney (BHK) cells. Cl 13 is a triple plaque-puri-
fied variant of ARM 53b derived from spleen cells of an adult
BALB/WEHI mouse persistently infected since birth with ARM
53b (9). The isolation of LCMV WE clones c2.2 and c54 has
been described (25). The new macrophage-, PBL-, CD4-, and
CD8-derived LCMV viruses were isolated from purified popula-
tions (
 
.
 
99%) of T cells and macrophages obtained from CD4
 
2
 
/
 
2
 
,
perforin
 
2
 
/
 
2
 
, and TNF-
 
a
 
2
 
/
 
2
 
 gene–disrupted mice. The isolation
of LCMV viruses was done by infectious center assay as described
(26). All viral isolates were plaque purified three times; virus
stocks grown in BHK cells and passage 1 or passage 2 levels were
used in experiments. The plaque purification procedure, prepara-
tion of stock virus in BHK cells, and titration of viral stocks by
plaquing has been described (9, 24). For virus overlay protein
binding assay (VOPBA; reference 23), virus was concentrated and
purified by precipitation with polyethylene glycol and renografin
density gradient centrifugation (27).
BALB/c ByJ mice maintained and bred in The Scripps Re-
search Institute were used for all experiments. These mice were
infected as adults (7–10 wk old) by intravenous inoculation of
2 
 
3
 
 10
 
6
 
 PFU of virus. Perforin
 
2
 
/
 
2
 
, CD4
 
2
 
/
 
2
 
, and TNF-
 
a
 
2
 
/
 
2
 
mice, as described (28, 29), had a mixed background of C57BL/6
and 129Sv. These mice were infected intracranially at birth with
10
 
3
 
 PFU of ARM 53b.
 
Purification of Lymphocyte Subsets and Macrophages.
 
PBLs were
purified by Ficoll-Hypaque gradient centrifugation of mouse
blood, as described (29, 30). In brief, heparinized blood was di- 
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luted in PBS, pH 7.2, layered into an equal volume of Ficoll-
Hypaque solution (Sigma-Aldrich), and spun at 600 
 
g
 
 for 15 min
at room temperature. Cells at the interface were collected, washed
in RPMI containing 10% FCS, and contaminating erythrocytes
were removed by lysis with 0.83% ammonium chloride. CD4
 
1
 
and CD8
 
1
 
 T cell subpopulations were isolated from spleen by
FACS
 
®
 
. In brief, spleens were dispersed by pressing through a
wire grid. Single-cell suspensions were marked using rat anti–
mouse CD8-allophycocyanin (APC; BD PharMingen) and rat
anti–mouse CD4-FITC (BD PharMingen) by incubating with
the antibodies at 4
 
8
 
C for 20 min. The cells were washed three
times with RPMI containing 5% FCS. After that, cells were
sorted so that the purity of each subset was 
 
.
 
99%. Isolation of
peritoneal macrophages was done as described previously (31). In
brief, C57BL/6 mice were injected with 3 ml of thyoglycollate
(Becton Dickinson) 1 wk before isolation of macrophages. The
macrophages were obtained by intraperitoneal lavage of the peri-
toneal cavity with PBS containing 1 mM EDTA. The prepara-
tion of macrophages was 
 
.
 
99% pure as determined by staining
with macrophage-specific monoclonal antibody F4/80 (32).
 
RNA Isolation, Nucleotide Sequence, and MnlI Digestion.
 
Total
RNA from BHK cells infected with the indicated viruses was iso-
lated by the TRI reagent method (Molecular Research Center,
Inc.). Purified RNA (1 
 
m
 
g) was transcribed to cDNA using 2 U
of avian myeloblastosis virus reverse transcriptase (RT; GIBCO
BRL) and then amplified by PCR using the Taq polymerase
(Boehringer). The RT-PCR products were sequence by the fmol
method (Promega).
MnlI digestion of 20 
 
m
 
l of the RT-PCR products was carried
out, and the products were run on a 2% Seakem ME agarose gel
(FMC Bioproducts) and visualized by ethidium bromide staining
as described (11).
 
CTL Assay.
 
The virus-specific CTL assay was quantitated by
a standard 
 
51
 
Cr-release assay (8, 9, 12). In brief, 
 
51
 
Cr-labeled
BALBCl7 cells (H-2
 
d
 
) and MC57 cells (H-2
 
b
 
), either uninfected
or infected 48 h previously with ARM 53b at a multiplicity of in-
fection of 1 PFU/cell, were employed as target cells. Effector cells
were prepared from the spleens of individual mice 7–8 d after in-
fection with 2 
 
3
 
 10
 
6
 
 PFU intravenously with virus. Lysis was
measured over a 5-h period at several effector/target ratios rang-
ing from 50:1 to 5:1. Samples were set up in triplicate (variance
was 
 
,
 
10%). The results are expressed as the percentage of specific
 
51
 
Cr release: [(sample release 
 
2
 
 spontaneous release)/(maximum
release 
 
2
 
 spontaneous release)] 
 
3
 
 100. Lysis of uninfected targets
mediated by effector cells has been subtracted from the infected
cell value to give LCMV-specific lysis.
 
Serum Virus Titers.
 
Serum virus titers were determined by
plaque assay on Vero cell monolayers (9).
 
VOPBA.
 
VOPBA was done as described (18, 23). In brief,
purified 
 
a
 
-DG was loaded on an SDS-PAGE, electrophoresed,
and transferred onto nitrocellulose (0.45-
 
m
 
m pore size). The ni-
trocellulose was incubated overnight with purified virus (10
 
7
 
PFU). After several washes with PBS, 0.1% Tween 20, the nitro-
cellulose was incubated with monoclonal antibodies specific for
LCMV GP. The proteins were detected with the enhanced
chemiluminescence procedure according to the manufacturer’s
instructions (Amersham Pharmacia Biotech).
 
Riboprobe Generation.
 
A 559-bp fragment of the LCMV NP
was amplified by PCR of a NP cDNA using the primer pair
5
 
9
 
-CGGAATTCAGTCCATGAGTGCACAGTGC and 5
 
9
 
-
CGGAATTCGAGAAACCTGCAGTCAATTC. A restriction
digest with EcoRI was performed in the PCR fragment to sub-
clone it into the EcoRI
 
 
 
site of the pSP70 vector (Boehringer).
After determining the orientation of the insert, a strand-specific
LCMV NP riboprobe was synthesized using T7 RNA poly-
merase (Promega) in the presence of digoxigenin labeling mix
(Boehringer [33]). An unrelated riboprobe labeled with digoxige-
nin and complementary to transcripts of the N protein of measles
virus served as a negative control in this study and was synthesized
as described previously (34). The amounts of synthesized ribo-
probes were determined by formaldehyde agarose gel electro-
phoresis.
 
In Situ Hybridization.
 
Spleens from three to five animals for
each experimental group were analyzed by in situ hybridization
(33) 3 and 5 d after infection with various LCMV isolates. Tissue
sections (6 
 
m
 
m thick) of fresh frozen tissue were collected on Su-
perFrost/Plus slides (Fisher Scientific) and fixed in 4% paraform-
aldehyde in phosphate buffer. Sections were acetylated by incu-
bation in 0.1 M triethanolamine (Sigma-Aldrich), 0.25% acetic
anhydride, subsequently treated with 0.1% Triton X-100/phos-
phate buffer, and prehybridized at room temperature in hybrid-
ization buffer (50% formamide [Sigma-Aldrich], 5
 
3 SSC, 2%
blocking reagent [Boehringer]) for 2 h. Hybridization with
digoxigenin-labeled riboprobes (50 ng/ml) was carried out over-
night in hybridization buffer at 688C. Sections were washed
twice at room temperature with 23 SSC and twice at 708C with
0.23 SSC for 30 min each. The digoxigenin-labeled riboprobe
was then detected with an antidigoxigenin alkaline phosphatase
conjugate (Boehringer) and NBT/BCIP color substrate (Boeh-
ringer). Developing times of the color reaction ranged from 4 to
10 h. Slides were counterstained with DAPI (Sigma-Aldrich),
mounted in AquaMount (Fisher Scientific), and analyzed by light
and UV microscopy.
Isolation of Splenic Cell Populations and Quantitation of LCMV-
infected Cells. Cell suspensions were prepared from the spleens
of mice infected 3, 5, 7, 15, and 20 d previously with various viral
variants by mechanic disruption of the spleens. Cells were immu-
nostained in PBS/2% (wt/vol) fetal bovine serum/0.2% (wt/vol)
NaN3 using as antibodies rat anti–mouse CD4-CyChrome, rat
anti–mouse CD8-APC, rat anti–mouse B220-PE, rat anti–mouse
CD11c-PE, and rat anti–mouse CD11b-APC (all from BD
PharMingen). A rat anti–mouse DEC-205 antibody (Serotec) was
used as primary antibody, and as a second antibody PE-labeled
F(ab9)2 mouse anti–rat IgG (Caltag) was used. After staining, cells
were fixed and permeabilized in PBS/1% fetal bovine serum (wt/
vol)/4% paraformaldehyde (vol/vol)/0.1% saponin (wt/vol). Af-
finity-purified antibody to LCMV NP (113) was conjugated to
Alexa-488 according to the protocol recommended by the manu-
facturer (Molecular Probes) and used for intracellular detection of
LCMV NP. Cells were acquired using a FACSCalibur™ flow
cytometer (Becton Dickinson). Dead cells were excluded on the
basis of forward and side light scatter. Data were analyzed using
CELLQuest™ software (Becton Dickinson).
Isolation of a-DG from Splenic Cell Populations. Splenic cell
populations were prepared from naive mice by mechanical dis-
ruption of the spleens. Cells were immunostained in HBSS
(GIBCO BRL)/1% (vol/vol) fetal bovine serum/1.2 mM EDTA
containing protease inhibitors (Boehringer) using antibodies rat
anti–mouse CD11c-biotin, rat anti–mouse CD4-CyChrome, rat
anti–mouse CD8-APC, and rat anti–mouse B220-PE (all from
BD PharMingen). After staining, the splenocytes were incubated
with Dynabeads M-280 Streptavidin (Dynal). The Dynabeads
coated with biotinylated CD11c were separated using a Dynal
Magnetic Particle Concentrator (MPC) for 2–3 min. The un-
bound cells were sorted by FACS® to insure purity of .98%.
The different cell populations (CD11c1, CD41, CD81, B2201,1252 Immunosuppression by Infection of Dendritic Cells
Table I. Characterization of LCMV Isolates Used in This Study
Virus isolate* Carrier mouse‡
LCMV-specific CTLs in spleen§
(E/T ratio of 50:1)
LCMV titer (PFU) per ml of serum
(15/30 d)
aa position 
1079 of Li
aa position
260 of GP¶
ARM 53b 80 ,50 K F
Cl 13 0 1 3 105/3 3 104 QL
Mac 13-3 CD4 ko mice 
150 d after infection
02   3 105/1 3 105 KL
Mac 14-1 0 1 3 106/2 3 105 KL
PBL 7-1 0 3 3 105/1 3 106 KL
PBL 6-4 0 1 3 104/2 3 105 NL
PBL 36-1 Perforin ko mice 
7 mo after infection
2.2 1 3 103/2 3 104 NL
PBL 36-2 0 1 3 104/1 3 103 NL
PBL 36-3 0.6 5 3 106/2 3 102 NL
PBL 36-4 6 3 3 104/1 3 103 NL
PBL 50-1 4.6 9.5 3 104/1 3 103 KI
PBL 50-2 0 3.3 3 103/1 3 102 KI
PBL 50-3 0 6 3 104/1.5 3 102 KI
PBL 66-1 0 5.3 3 103/3.3 3 102 KL
PBL 66-2 0 1.7 3 104/,50 K L
PBL 66-3 0 5 3 105/2 3 102 KL
PBL 67-3 0 2.1 3 105/1 3 104 QL
PBL 67-4 0 1.4 3 104/5 3 102 QL
CD8-4 Perforin ko mice 
24 d after infection
60 ,50 K F
CD8-5 78 ,50 K F
CD8-6 80 ,50 K F
CD8-7 80 ,50 K F
CD8-8 73 ,50 K F
CD4-1 60 ,50 K F
CD4-2 63 ,50 K F
CD4-5 80 ,50 K F
TNCD8-1 TNF-a ko mice 
3 mo after infection
02   3 102/1 3 102 ND L
TNCD8-2 0 3 3 104/2 3 104 ND L
TNCD4-1 0 3 3 103/2 3 104 ND L
TNCD4-2 0 1.1 3 104/2 3 102 ND L
TNPBL2-1 0 2 3 102/,50 ND L
TNPBL2-2 0 2 3 103/3 3 102 ND L
TNPBL4-1 11 4 3 103/2 3 102 ND L
TNPBL4-2 0 3 3 104/,50 ND L
TNB4-1 48 ,50 ND F
TNB4-2 80 ,50 ND F
TNB2-1 78 ,50 ND F
TNB2-2 60 ,50 ND F
BALB/c ByJ mice were infected intravenously with 2 3 106 PFU of isolated virus. The CTL response was checked at day 7 after infection and viral
titers in sera were measured at days 15 and 30 after infection. The data shown are the averages of values from two to four mice per group.
*Virus isolates were obtained by picking plaques formed by macrophages (Mac), CD41 cells (CD4), CD81 cells (CD8), PBLs, and brain homoge-
nate (TNB). TNCD8, TNCD4, and TNPBL refer to isolates from CD81, CD41 cells, and PBLs, respectively, of TNF-a ko mice.
‡These virus isolates had been selected in immunocompromised mice (CD4 ko, perforin ko, and TNF-a ko) at different times after inoculation.
§These values are percentages of 51Cr release from BALB/c Cl7 (H-2d) targets at an E/T ratio of 50:1.
iThe cDNA that encodes aa 1079 of the L gene was amplified by PCR and the PCR product was sequenced as described in Materials and Methods.
¶The aa at position 260 of GP1 was checked by the RT-PCR MnlI digestion technique described in Materials and Methods. The RT-PCR prod-
ucts were sequenced.1253 Sevilla et al.
and total splenocytes) were lysed in 50 mM Hepes, pH 7.5/200
mM NaCl/5 mM MgCl2/5 mM CaCl2/1% (wt/vol) NP-40/1.2
mM EDTA/1 mM PMSF for 45 min on ice. After centrifugation
for 10 min at 14,000 rpm, the supernatants were incubated with
20 ml of jacalin coupled to agarose (Vector Laboratories) over-
night at 48C. The matrix was washed three times in lysis buffer,
and the eluted proteins were resolved in a 6% SDS-polyacryl-
amide gel for VOPBA with 108 PFU of LCMV Cl 13. a-DG
from MC57 cells was isolated using the same procedure.
Results
Characterization of LCMV Isolates from Immune and CNS
Cells of Persistently Infected Mice. To evaluate the conse-
quence of selection by immune pressure on the viral qua-
sispecies generated in a persistently infected mouse, we
isolated viruses from mice immunocompromised by dis-
ruption of either CD4, perforin, or TNF-a genes. LCMV
ARM 53b was used to initially infect each group of knock-
out (ko) mice. Viruses were recovered by cocultivation on
permissive Vero cells from purified populations (.99%
pure) of individual CD41 and CD81 T cells, macrophages,
and PBLs. Cell populations were purified using mono-
clonal antibodies and flow cytometry. In addition, viruses
were isolated from the CNS of such persistently infected
mice. Such viruses persist and replicate exclusively in neu-
rons (35, 36). Isolated viruses were three times plaque puri-
fied, and their biological properties were evaluated by two
criteria: (a) the ability to elicit an LCMV-specific CTL re-
sponse at day 7–8 after infection, and (b) their ability to
cause a persistent infection  in vivo. For these studies, a
minimum of three mice were challenged with each clonal
virus isolate. The results indicated that viruses isolated from
lymphocytes or macrophages obtained from CD4, perforin,
and TNF-a ko mice persistently infected for at least 7 mo
failed to generate LCMV-specific CTL responses and
caused a persistent infection (Table I). These viruses are re-
ferred to as CTL2P1. In contrast, viruses isolated from the
CNS of TNF-a ko mice elicited a potent LCMV-specific
CTL response, which cleared the virus within 2 wk and left
no evidence of persistent infection. These viruses are re-
ferred to as CTL1P2. Interestingly, viruses isolated from
CD41 and CD81 cells within the first 24 d of the persistent
infection showed the same phenotype (CTL1P2) as the pa-
rental ARM 53b (Table I).
An Aliphatic aa at Position 260 of the Viral Glycoprotein Is
Associated with the CTL2P1 Phenotype of LCMV Variants.
To identify the genetic changes of the CTL2P1 viruses, the
sequence of the viral GP and selected regions of the viral
polymerase (L) was determined using two independent
strategies. First, to determine the aa in 260 of GP1, an ini-
tial screen using a cDNA copy of isolated viral RNA,
treated with MnlI enzyme and gel electrophoresis (11), was
employed followed by direct sequencing of the entire GP1.
Both the MnlI screen and direct sequencing indicated that
the vast majority (21 out of 24) of CTL2P1 viruses had an
L at 260 of GP. In contrast, those viruses with the pheno-
type CTL1P2 (12 out of 12) had an F at this aa position.
Three CTL2P1 variants, PBL 50-1, PBL 50-2, and PBL
50-3, did not show the expected 202- and 160-bp frag-
ments after MnlI digestion of the corresponding 362-bp
PCR products (11). Sequence analysis of these three viruses
indicated that they possessed a different aliphatic aa, I, at
position 260 of GP1. Sequence analysis of GP1 from both
CTL2P1 and CTL1P2 variants showed that several viruses
exhibited additional changes to the one in position 260
(data not shown). However, of all these viruses showed the
same CTL2P1 phenotype as those with the single aa substi-
tution F260L. Thus, it seems unlikely that the additional
changes contributed to the CTL2P1 phenotype.
The change K1079Q in the L protein did not correlate
with the CTL2P1 phenotype (Table I). These data suggest
that any role played by the polymerase in the CTL2P1
Figure 1. VOPBA with puri-
fied a-DG and LCMV variants.
Decreasing amounts (1, 0.1, and
0.01 mg) of purified a-DG were
incubated with 107 PFU of each
viral isolate and then with virus-
specific antibody as described in
Materials and Methods. The top
panels show the VOPBA of
CTL1P2 LCMV isolates (ARM
53b, CD8-4, CD4-1, and
TNFB2-1). The phenotype as
well as the aa in position 260 of
GP1 (F) is shown under each
blot. The bottom panel shows
the VOPBA of CTL2P1 LCMV
isolates (Cl 13, PBL 7-1, PBL
36-4, PBL 50-1, PBL 67-3, and
TNPBL4-2). The CTL  P phe-
notype is indicated under the
name of each isolate and the aa
in position 260 of GP1 (L or I).1254 Immunosuppression by Infection of Dendritic Cells
phenotype does not map specifically to aa position 1079. It
is plausible that other aa positions within the L protein
could contribute to the CTL2P1 phenotype. Nevertheless,
reassortants made between Cl 13 (CTL2P1) and parental
ARM 53b (CTL1P2) viruses that differ only in two posi-
tions, one in GP 260 (F260L) and the other in the L
(K1079Q), indicated that both the CTL2P1 phenotype
(12) and the binding and infection of a-DG1 cells mapped
to the S RNA of Cl 13 (Tishon, A., and M.B.A. Oldstone,
unpublished observations). The S RNA encodes the viral
NP that is identical between Cl 13 and ARM, and the vi-
ral GP that differs in a single aa, thus strongly suggesting
that the mutation in the GP but not in the polymerase is
likely to be important for the CTL2P1 phenotype. As this
biologically important aa mutation occurred in the seg-
ment of GP (GP1) implicated in binding to the virus re-
ceptor, we turned our attention to the analysis of virus–
a-DG binding.
High Affinity Binding of Viral Variants to the a-DG Recep-
tor Correlates Directly with the CTL2P1 Phenotype. To es-
tablish the role of aa 260 in the binding to a-DG, several
virus isolates with either a CTL2P1 or a CTL1P2 pheno-
type were quantitatively assayed for their binding affinity to
a-DG. All LCMV variants with an L or I in position 260
of GP1 showed high binding affinity to a-DG, comparable
to that of Cl 13, with binding of at least 1 log and often 2–3
logs greater than that observed with CTL1P2 viruses that
contained F at GP1 aa 260 (Fig. 1). Competitive inhibition
binding assays using soluble a-DG and 10 different viral
strains or variants showed that high affinity virus binders
were routinely blocked by 1–4 nM soluble a-DG (33%
blocking) whereas in contrast, low affinity viral binders re-
Figure 2. Anatomic locations of viral nucleic acids within the spleen 3 d after infection with LCMV ARM 53b, Cl 13, and representative CTL2P1
(PBL 36-4, PBL 67-3, PBL 50-3, TNPBL4-2, and Mac 13-3) and CTL1P2 variants (TNB2-1 and TNB4-1) of ARM 53b. In situ hybridization was per-
formed using a digoxigenin-labeled riboprobe specific for LCMV NP. In spleen sections from BALB/c ByJ mice infected intravenously with 2 3 106
PFU of virus ARM 53b, TNB2-1, or TNB4-1, the nucleic acids localized predominantly in the red pulp (RP). Using identical conditions, the nucleic
acids of CTL2P1 virus isolates localized within the white pulp (WP) or its marginal zone (MZ). All panels are shown at the same magnification. A higher
power view is shown in the inset for ARM 53b– and Cl 13–infected mice. The arrows indicate viral nuleic acid detected in individual cells.1255 Sevilla et al.
quired .400 nM soluble a-DG to block binding to a-DG
cells (data not shown). Taken together, these findings indi-
cated that an aliphatic aa–like L or I in position 260 of GP1
of LCMV viruses is associated with high affinity binding to
a-DG, whereas those viruses containing an aromatic (F) aa
at this position bound at least 1 and most often at 2–3 logs
lower affinity to a-DG.
High Affinity Binding CTL2P1 Variants Preferentially Rep-
licate in CD11c1 and DEC-2051 Cells Located in the White
Pulp of the Spleen. Next, we analyzed the anatomic distri-
bution of CTL2P1 and CTL1P2 viruses in the spleens of
adult immunocompetent mice infected 3 d previously with
2 3 106 PFU of virus intravenously. For these studies, four
sections from at least four independently inoculated mice
were examined using a digoxigenin-labeled probe to
LCMV NP and in situ hybridization. The results indicated
that CTL2P1 viruses localized exclusively in cells of the
marginal zone and white pulp (Fig. 2). In contrast,
CTL1P2 variants localized primarily to cells within the red
pulp (Fig. 2). By 5 d after infection, the spleens from mice
infected with CTL2P1 viruses exhibited the beginning of
an extensive destruction of lymph follicle structures similar
to previous reports (7, 37). Infection with the CTL1P2 vi-
ruses had no such effect (data not shown).
To identify specific cells in the spleen that were infected
by LCMV, suspensions of single cells prepared from indi-
vidual spleens were labeled with specific monoclonal anti-
bodies to cell surface markers coupled to a fluorochrome
probe. This was complemented with the use of an antibody
to LCMV NP directly coupled to a different and distinct
fluorochrome, thereby allowing detection of viral antigen
in the specifically marked cell type. CTL2P1 viruses prima-
rily infected CD11c1 (cellular marker of most DCs in
mouse lymphoid tissue [38]) and DEC-2051 (antigen ex-
pressed on interdigitating DCs in lymphoid tissues [39])
cells with only minimal to negligible infection of CD11b1,
B2201, CD41, and CD81 cells, as indicated in the graph
and a summary of the experiments shown in the table un-
der the graph in Fig. 3 B. In contrast, as shown in Fig. 3 A,
there was minimal infection of both CD11c1 and DEC-
2051 cells by the CTL1P2 viruses. We next quantified the
number of CD11c1 and DEC-2051 cells infected and de-
termined the in vivo replication kinetic over the first 20 d
of infection. At day 7 after infection, 60% of CD11c1 cells
and 17% of DEC-2051 cells were infected with CTL2P1
viruses. Thereafter, the number of DEC-2051 cells in-
fected by CTL2P1 viruses markedly increased over the
next week so that by day 15, .80% of DEC-2051 cells
contained LCMV antigens (Fig. 4, A and B, show results
from mice infected with Cl 13). In contrast, significantly
fewer CD11c1 and DEC-2051 cells were infected by
CTL1P2 viruses (Fig. 4 B shows results from mice infected
with ARM 53b). Over the 20-d observation period, ,1%
of CD41, CD81, B2201, and CD11b1 cells were infected
with CTL2P1 or CTL1P2 viruses. These data indicate:
first, that DCs are the primary cell infected in vivo  by
CTL2P1 LCMV variants; second, that CTL2P1 viruses as-
toundingly infect .50% of CD11c1 and DEC-2051 cells
but ,1% of CD11b1, B, CD4, and CD8 T lymphocytes;
and third, that CTL1P2 viruses fail to infected significant
numbers of DCs. Thus, viral variants with a CTL2P1 phe-
notype bound with high affinity to the a-DG receptor and
Figure 3. Comparative levels of infectivity
in immune cells caused by CTL2P1 and
CTL1P2 viral variants. In each experiment,
four adult BALB/c ByJ mice were injected
intravenously with 2 3 106 PFU of virus, and
3 d after infection a pooled splenocyte sus-
pension was prepared from each mouse (see
Materials and Methods). Each cell population
was labeled with cell-specific monoclonal an-
tibodies to CD4, CD8, B220, CD11c, DEC-
205, and CD11b. Subsequent intracellular
staining using specific antibody to LCMV NP
(antibody 113) was performed, followed by
FACS®. The graph represents percentages of
cells in each subset infected with ARM 53b
(A) or Cl 13 (B). Summarized below are the
percentages of infected antigen-presenting
cells (CD11c, CD11b, B220, and DEC-2051
cells) or CD4 and CD8 T cells infected with
these viruses. The term “other cells” refers to
the sum of percentages for infected CD11b1,
B2201, CD41, and CD81 T cells. (A) Infec-
tion of cell populations by CTL1P2 viruses.
(B) Infection of cell populations by CTL2P1
viruses.1256 Immunosuppression by Infection of Dendritic Cells
preferentially infected DEC-2051 and CD11c1 cells of the
marginal zone and white pulp in the spleen. This pheno-
type is referred to as IS1P1. LCMV variants that failed both
to suppress immune responses and to establish persistence
are referred to as IS2P2.
Identification of a Second aa Site in GP1 Associated with the
IS1P1 Phenotype. In the next series of experiments, we
evaluated whether another strain of LCMV, WE, which
has 94% identity at the aa level with ARM 53b or Cl 13
(25), exhibited the same correlation between immunosup-
pression, viral persistence, high affinity binding to a-DG,
and preferential infection of CD11c1 and DEC-2051 cells
in the white pulp. Two clonal isolates of the LCMV-
WE54 parental strain, WE c2.2 and WE c54, were ana-
lyzed. Inoculation of adult immunocompetent mice with
2 3 106 PFU of WE c54 intravenously led to a negligible
Figure 4. Replication of
CTL2P1 and CTL1P2 viruses in
DCs. Four adult BALB/c ByJ
mice were infected intravenously
with 2 3 106 PFU of either
ARM 53b or Cl 13. CD11c1
and DEC-2051 cells obtained
from pooled spleens made into
single splenocyte suspensions
were labeled with specific anti-
bodies for these cell subsets (see
Materials and Methods). (A)
Replication of Cl 13 in DCs. Af-
ter intracellular staining with the
monoclonal antibody specific to
LCMV NP (113) and FACS®,
dot plots were obtained that
showed double-positive cells for
113-Alexa and DEC-2051 (top)
or CD11c1 (bottom) cells. The
numbers in each dot plot denote
the percentage of 113-Alexa1
cells over the background in
each cell population. (B) Curve
plots show the replication of Cl
13 and ARM 53b in DEC-2051
and CD11c1 cells over a 20-d
observation period.
Figure 5. Comparison of binding affini-
ties for the WE c54 and WE c2.2. isolates.
(A) Biological properties of LCMV WE c54
and WE c2.2 as evaluated by the generation
of an LCMV-specific CTL response at day
7 after infection and the ability or inability
to clear the virus from the serum. CTL re-
sponses at day 7 are indicated as the per-
centage of 51Cr release from BALB/c ByJ
(H-2d) targets at an effector/target ratio of
50:1, and the amount of infectious virus in
serum is expressed as PFU per ml of plasma
at day 30 after infection. The aa at position
153 of GP1 is indicated. (B) Comparison of
the number of various splenic cell popula-
tions infected by LCMV WE c54 and WE
c2.2. The results are shown as percentages
of infected cells in each population as deter-
mined by FACS®. (A) VOPBA with de-
creasing amounts (1, 1021, 1022, and 1023
mg) of purified a-DG blotted with 107 PFU
of WE c54 or WE c2.2 virus detected with
specific anti-GP LCMV antibodies as de-
scribed in Materials and Methods. NIL, not
detectable; ORF, open reading frame.1257 Sevilla et al.
anti-LCMV CTL response 7 d after virus challenge and to
the establishment of a persistent viral infection (Fig. 5 A).
In contrast, mice given WE c2.2 virus generated an effec-
tive CTL response that cleared virus and terminated the in-
fection 8 d after inoculation. Thus, WE c54 and WE c2.2
exhibited distinct CTL2P1 and CTL1P2 phenotypes, re-
spectively.
Reassortants between the two WE variants (WE c54 and
WE c2.2) and ARM 53b mapped the CTL2P1 phenotype
of WE c54 to the S RNA. Sequence analysis showed that
the NPs of WE c54 and WE c2.2 were identical, but the
GPs of these two viruses differed at a single aa position
(WE c54 S153 and WE c2.2 F153) in GP1 (40). WE c54
bound with 3 logs higher affinity to a-DG than did WE
c2.2 (Fig. 5 C). These results implicate, in addition to aa
260, aa 153 of GP1 in the binding of GP1 to a-DG. Ex-
periments analyzing the anatomic distribution of WE c54
in the spleen after 3 d of virus infection showed that this
CTL2P1 virus was restricted to the white pulp of the
spleen. In contrast, WE c2.2 (CTL1P2 phenotype) was
found preferentially in the red pulp (data not show).
FACS® analysis of cells obtained from the spleen showed
that WE c54 but not WE c2.2 preferentially infected
CD11c1 and DEC-2051 cells (Fig. 5 B).
Expression of a-DG in DCs. Replication of LCMV in
CD11c1 and DEC-2051 DCs was associated with the
CTL2P1 phenotype (Figs. 3–5, and Table I). The final ex-
periment evaluated expression of a-DG in CD11c1,
CD41, CD81, and B2201 cells. The lack of high affinity
antibodies to DEC-205 prevented analysis of DEC-2051
cells. Specific cell populations were isolated using high af-
finity cell type–specific antibodies coated on magnetic
beads. Cells were lysed and a-DG enriched from solubi-
lized total protein extract by microscale affinity purification
using a jacalin–agarose matrix that preferentially binds to the
mucin-type, O-linked glycans that are abundant on a-DG
(41, 42). After the removal of unspecifically bound material,
jacalin-bound glycoproteins were eluted and separated by
SDS-PAGE, and subjected to VOPBA with LCMV Cl 13.
LCMV binding activity was only detected in CD11c1 cells
(Fig. 6). Interestingly, comparing equivalent numbers of
cells, the average signal of a-DG expression in total spleno-
cytes was significantly lower then that of CD11c1 cells (Fig.
6). This suggests that CD11c1 cells represent a major cell
population in the spleen expressing a-DG.
Discussion
This paper makes three important points. First, virus–
DC interaction in vivo can be a leading event in the initia-
tion of suppression of host immune response and the estab-
lishment of a persistent infection. Second, a crucial role of
virus–receptor interaction is involved in the initiation of
immunosuppression for LCMV and may be important for
other viruses. Third, within the spleen, a-DG is highly ex-
pressed in CD11c1 cells but not on CD11b1, T, or B cells.
We demonstrate that infection with strains and variants of
LCMV that have a preferential tropism for DCs resulted in
a suppression of the host immune system. Those viral vari-
ants with higher receptor affinity binding can be selected in
vivo within the replicating viral quasispecies. Such selec-
tion results in the infection of DCs, which preferentially
express the virus cellular receptor a-DG, leading to a gen-
eralized suppression of immune responses, including the
anti-LCMV CTL response required for terminating the in-
fection. Further, a-DG is expressed in high concentrations
on CD11c1 cells, and this molecule may serve as a useful
marker in the segregation of DC populations.
Using mice whose immune system was compromised by
different means allowed us to evaluate the selective pres-
sures involved in the emergence of CTL2P1 viral variants.
Virus isolates from lymphocytes and macrophages of CD4
ko, perforin ko, and TNF-a ko persistently infected mice
exhibited a CTL2P1 phenotype when inoculated into
adult immunocompetent mice. The CTL2P1 variants had
an L or I in aa position 260 of GP1, instead of F found in
the same position of CTL1P2 viruses, implying the impor-
tance of this aa position in the selection of the CTL2P1
variants. As the same aa substitution of F®L/I at position
260 of GP1 was selected for in CD4 ko, perforin ko, and
TNF-a ko mice, it is unlikely that selection of CTL2P1
variants is driven by the immune system. These viral vari-
ants are being produced in the replicating viral quasispecies
and are able to adapt to favorable environments with the
fittest of mutants chosen out from the viral quasispecies (43,
44). In vivo competition assays between ARM 53b and Cl
13 showed that Cl 13 has a higher fitness over ARM 53b
for immune cells in the white pulp of the spleen (7, 10,
11). Our data indicate that those viral variants with in-
creased binding receptor affinity may be selected from
within the replicating viral quasispecies to bind to CD11c1
and DEC-2051 DCs. To our knowledge, this is the first in
vivo report that selection occurs for viruses to enter specific
cells such as the DC population. The selective pressure is
likely based on the interaction of the virus with its recep-
tor, thereby offering a marked advantage to the virus in ini-
tiating the dysfunction or destruction of the host pro-
fessional antigen-presenting cells, thereby aborting the
necessary host immune responses required to terminate the
viral infection. By contrast and in other instances, selection
Figure 6. VOPBA with a-DG
purified from fibroblasts (MC57
cells), total splenocytes, CD41,
CD81, B2201, or CD11c1 cells
incubated with LCMV Cl 13.
a-DG purified from different
numbers of cells (2 3 105 MC57
cells, 106 and 107 total spleno-
cytes, and 2 3 106 CD11c1,
CD41, CD81, and B2201 cells)
was resolved in a 6% SDS-poly-
acrylamide gel. Incubation was
with 108 PFU of Cl 13 and then
with virus-specific antibody (see Materials and Methods). The arrow indi-
cates the band corresponding to a-DG. The variability in molecular
weights of a-DG from MC57 cells, total splenocytes, and CD11c1 cells
likely reflects different glycosylation patterns.1258 Immunosuppression by Infection of Dendritic Cells
of viral variants by the host immune responses have been
well established with influenza and HIV infections, provid-
ing an advantage to the virus over the host (for reviews, see
references 45–47). Our observations are unique and differ-
ent, as virus selection is based on virus receptor binding af-
finity to an essential cell involved in generating host im-
mune responses, and this in turn aborts or reduces the basic
adoptive host mechanism for controlling infection. This vi-
rus–DC type of selection in vivo may apply to other viruses
that both cause immunosuppression or persistent infections
and that infect/bind to DCs, i.e., HIV and measles.
The difference in tropism in the spleen between
CTL2P1 and CTL1P2 viral variants was remarkable. At
day 7 after infection, almost 60% of DCs were infected by
the CTL2P1 variants, making them excellent targets for
the destruction by the host immune system. In contrast,
15% or less of DCs were infected by the CTL1P2 variants
at day 7 after infection according to the sensitivity of the
assay, resulting in the majority of DCs being protected
from either CTL lysis (7, 30) or direct viral effect on DC
function (1, 2). The sustained replication of virus in
CD11c1 and enhanced replication in DEC-2051 cells
(.80% of such cells over the 2-wk observation period)
suggest the possibility of ongoing infection of DCs migrat-
ing and repopulating the spleen. Experiments to analyze
the kinetics of DC migration from the bone marrow, turn-
over and survival during LCMV infection, and functional-
ity of infected DCs are currently under evaluation. Prelim-
inary data suggest that the function of DCs, including
expression of IL-12 and B7-1 (Sevilla, N., S. Kunz, and
M.B.A. Oldstone, unpublished data) is affected by IS1P1
but not by IS2P2 viruses.
In addition to the influence of a bulky aromatic aa (F) or
a small aliphatic aa (L/I) in GP1 residue 260 in affinity
binding to the LCMV cellular receptor a-DG, studies with
CTL2P1 and CTL1P2 WE virus variants indicated that the
aromatic aa in GP1 residue 153 also prevented high affinity
binding to a-DG. This was corrected by a substitution to S
for F in GP1 aa 153. With the S in GP1 aa 153, WE strains
bound at 2–3 logs higher affinity to a-DG and infected 20-
fold more CD11c1 and DEC-2051 DCs than did the low
affinity binding CTL1P2 variant WE c2.2. These data sug-
gest a generality in the DC–a-DG virus interactions for
LCMV strains.
Our studies documented the high expression of a-DG on
DCs. A comparison between total splenocytes and CD11c1
cells indicated that CD11c1 cells were the major cell ex-
pressing a-DG in the spleen. As shown in Fig. 6, sixfold
fewer CD11c1 cells had a fourfold enhanced concentration
of a-DG over the amounts found in total spleen. Further,
neither T, B, nor CD11b1 cells expressed detectable
amounts of a-DG. As no more than 1% of the total spleno-
cytes are CD11c1, the source of a-DG we observed in the
total splenic population was due primarily to CD11c1 cells.
DCs play a pivotal role in T cell activation and thus a
critical role in initiating antiviral immunity (48). Studies
with several DNA and RNA viruses (49–51) revealed that
DCs are the most effective antigen-presenting cell for the
stimulation of CTL responses. A cardinal feature of IDCs is
the strong capacity to stimulate antigen-specific naive T
cells to proliferate, secrete cytokines, and express CD40L
(for a review, see reference 52). It would be a selective ad-
vantage for a virus to infect and impair the function of
DCs. Such a scenario has been postulated to occur, based
on in vitro studies with measles virus (53, 54), HIV (55,
56), and HSV-1 (57) infections. The studies presented here
clearly document a selective advantage for a virus to di-
rectly interact with DCs in vivo, and provides a model sys-
tem to dissect the molecules involved and the conse-
quences of virus–DC interactions.
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